www.dailypolitical.com ·
Zymeworks Nasdaqzyme Releases Quarterly Earnings Results Misses Estimates by 0 49 Eps
Topic context
This topic has been covered 270781 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedZymeworks' earnings miss reflects a revenue cliff due to milestone timing, not operational deterioration. The company's value hinges on the upcoming FDA decision for zanidatamab. Commercial mechanism is weak—no direct product price, supply, or margin impact beyond the single company's stock valuation. Sector PHARMA_BIOTECH is selected due to the regulatory catalyst, but impact is company-specific and binary.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Zymeworks (NASDAQ: ZYME) reported Q1 2026 loss of $0.59 per share, missing estimates by $0.49.
- Revenue was $2.41 million, down 91.1% YoY and far below $24.38 million consensus.
- Net loss of $44.2 million due to absence of non-recurring milestones from 2025.
- Cash reserve of $403.8 million; PDUFA date for zanidatamab set for August 25, 2026.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com